Identification

Name
Fulvestrant
Accession Number
DB00947  (APRD00654)
Type
Small Molecule
Groups
Approved, Investigational
Description

Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

Structure
Thumb
Synonyms
  • ICI 182,780
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FaslodexSolution50 mgIntramuscularAstra Zeneca2004-06-14Not applicableCanada
FaslodexInjection50 mg/mLIntramuscularAstra Zeneca Lp2002-04-26Not applicableUs
FaslodexInjection, solution250 mg/5mlIntramuscularAstra Zeneca2004-03-10Not applicableEu
FaslodexInjection, solution250 mg/5mlIntramuscularAstra Zeneca2004-03-10Not applicableEu
Categories
UNII
22X328QOC4
CAS number
129453-61-8
Weight
Average: 606.771
Monoisotopic: 606.316607085
Chemical Formula
C32H47F5O3S
InChI Key
VWUXBMIQPBEWFH-LQKBAPIOSA-N
InChI
InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29?,30+,41?/m1/s1
IUPAC Name
(1S,9R,11S,14S,15S)-15-methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-5,14-diol
SMILES
[H][[email protected]@]12CC[[email protected]](O)[[email protected]@]1(C)CC[[email protected]@]1([H])C2[[email protected]](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=CC(O)=CC=C12

Pharmacology

Indication

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

Structured Indications
Pharmacodynamics

Fulvestrant for intramuscular administration is an estrogen receptor antagonist without known agonist effects.

Mechanism of action

Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines.

TargetActionsOrganism
AEstrogen receptor alpha
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 3 to 5 L/kg
Protein binding

99% (mainly VLDL, LDL, and HDL)

Metabolism

Metabolism of fulvestrant appears to involve combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids, including oxidation, aromatic hydroxylation, conjugation with glucuronic acid and/or sulphate at the 2, 3 and 17 positions of the steroid nucleus, and oxidation of the side chain sulphoxide. Identified metabolites are either less active or exhibit similar activity to fulvestrant in antiestrogen models. Studies using human liver preparations and recombinant human enzymes indicate that cytochrome P-450 3A4 (CYP 3A4) is the only P-450 isoenzyme involved in the oxidation of fulvestrant; however, the relative contribution of P-450 and non-P-450 routes in vivo is unknown.

Route of elimination

Fulvestrant was rapidly cleared by the hepatobiliary route with excretion primarily via the feces (approximately 90%). Renal elimination was negligible (less than 1%).

Half life

40 days

Clearance
Not Available
Toxicity

There is no clinical experience with overdosage in humans.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fulvestrant.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Fulvestrant.Experimental
AmiodaroneThe metabolism of Fulvestrant can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Fulvestrant can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Fulvestrant can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fulvestrant can be decreased when combined with Atomoxetine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Fulvestrant.Approved, Investigational
BoceprevirThe metabolism of Fulvestrant can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Fulvestrant can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fulvestrant can be decreased when it is combined with Bosentan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fulvestrant.Approved
CarbamazepineThe metabolism of Fulvestrant can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Fulvestrant can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe metabolism of Fulvestrant can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fulvestrant can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Fulvestrant can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fulvestrant can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Fulvestrant can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Fulvestrant can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fulvestrant.Approved, Investigational
CyclosporineThe metabolism of Fulvestrant can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Fulvestrant.Experimental
DabrafenibThe serum concentration of Fulvestrant can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Fulvestrant can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fulvestrant can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Fulvestrant can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fulvestrant can be decreased when combined with Delavirdine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fulvestrant.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Fulvestrant.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fulvestrant.Approved
DihydroergotamineThe metabolism of Fulvestrant can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Fulvestrant can be decreased when combined with Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fulvestrant.Approved, Investigational
DoxycyclineThe metabolism of Fulvestrant can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fulvestrant can be decreased when combined with Dronedarone.Approved
EnzalutamideThe serum concentration of Fulvestrant can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Fulvestrant can be decreased when combined with Erythromycin.Approved, Vet Approved
FluconazoleThe metabolism of Fulvestrant can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Fulvestrant can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fulvestrant can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fulvestrant can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fulvestrant can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Fulvestrant can be increased when it is combined with Fusidic Acid.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Fulvestrant.Experimental
IdelalisibThe serum concentration of Fulvestrant can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fulvestrant can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Fulvestrant can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Fulvestrant can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Fulvestrant can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fulvestrant can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fulvestrant can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Fulvestrant can be decreased when combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Fulvestrant.Experimental
LopinavirThe metabolism of Fulvestrant can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Fulvestrant can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Fulvestrant can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fulvestrant can be increased when combined with Lumacaftor.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Fulvestrant.Experimental
MifepristoneThe serum concentration of Fulvestrant can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Fulvestrant can be decreased when it is combined with Mitotane.Approved
NefazodoneThe metabolism of Fulvestrant can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fulvestrant can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fulvestrant can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fulvestrant can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Fulvestrant can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Fulvestrant can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Fulvestrant.Experimental, Investigational
OsimertinibThe serum concentration of Fulvestrant can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Fulvestrant.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fulvestrant.Approved, Vet Approved
PalbociclibThe serum concentration of Fulvestrant can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Fulvestrant can be increased when combined with Pentobarbital.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Fulvestrant.Experimental
PhenobarbitalThe metabolism of Fulvestrant can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Fulvestrant can be increased when combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Fulvestrant can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Fulvestrant can be increased when combined with Primidone.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Fulvestrant.Experimental
RanolazineThe metabolism of Fulvestrant can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Fulvestrant can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fulvestrant can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fulvestrant can be increased when combined with Rifapentine.Approved
SaquinavirThe metabolism of Fulvestrant can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Fulvestrant can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fulvestrant can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fulvestrant can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Fulvestrant can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Fulvestrant can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Fulvestrant can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Fulvestrant can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Fulvestrant can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Fulvestrant can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Fulvestrant can be decreased when it is combined with Tocilizumab.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fulvestrant.Approved, Investigational
VenlafaxineThe metabolism of Fulvestrant can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fulvestrant can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Fulvestrant can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Fulvestrant can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N: Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. [PubMed:15950373]
  2. Kabos P, Borges VF: Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother. 2010 Apr;11(5):807-16. doi: 10.1517/14656561003641982. [PubMed:20151846]
  3. Bross PF, Cohen MH, Williams GA, Pazdur R: FDA drug approval summaries: fulvestrant. Oncologist. 2002;7(6):477-80. [PubMed:12490735]
External Links
Human Metabolome Database
HMDB15082
KEGG Drug
D01161
PubChem Compound
17756771
PubChem Substance
46508664
ChemSpider
21475029
BindingDB
50169743
ChEBI
31638
ChEMBL
CHEMBL1712246
Therapeutic Targets Database
DAP000319
PharmGKB
PA164747170
IUPHAR
1015
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fulvestrant
ATC Codes
L02BA03 — Fulvestrant
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (520 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceAdvanced Metastatic Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Solid Tumors With an Alteration of the PIK3CA Gene / Estrogen Receptor Positive Breast Cancer1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentEstrogen Receptor Positive / Invasive Breast Carcinoma / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentEstrogen Receptor Positive / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1Active Not RecruitingTreatmentHormone Receptor Positive, HER2-negative, Advanced Breast Cancer1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceNormal Healthy Volunteers1
1CompletedOtherHealthy Volunteers1
1CompletedOtherSolid Malignancies1
1CompletedTreatmentAdvanced Breast Cancer1
1CompletedTreatmentAdvanced Solid Malignancies / Breast Cancer - ER+, HER2 - / Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation1
1CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1CompletedTreatmentMalignant Lymphomas / Tumors, Solid1
1Not Yet RecruitingOtherPharmacokinetics1
1Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1RecruitingOtherCancer, Breast1
1RecruitingTreatmentAdvanced Solid Tumors / Cancer, Breast / Prostate Cancer1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentCancer, Breast3
1RecruitingTreatmentCancer, Breast / Tumors, Solid1
1RecruitingTreatmentHER2-Negative Breast Cancer / Metastatic Epithelial Ovarian Cancer / Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer1
1RecruitingTreatmentNeoplasms, Breast1
1RecruitingTreatmentNeoplasms / Neoplasms, Breast1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL) / Non-Hodgkin's Lymphoma, Solid Cancers / Solid Cancers1
1RecruitingTreatmentPostmenopausal Women With ER+ HER2- Primary Breast Cancer1
1WithdrawnTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2CompletedTreatmentER+ Breast Cancer / FGFR Inhibition, Pharmacokinetics, Biomarkers1
1, 2Not Yet RecruitingTreatmentCancer, Ovarian1
1, 2Not Yet RecruitingTreatmentColorectal Cancers1
1, 2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
1, 2RecruitingTreatmentAdvanced Estrogen Receptor Positive HER2- Breast Cancer1
1, 2RecruitingTreatmentAdvanced and Metastatic Breast Cancer1
1, 2RecruitingTreatmentCancer, Breast / Carcinoma, Ductal, Breast / Neoplasms, Breast1
1, 2RecruitingTreatmentEstrogen Receptor Positive Breast Cancer1
1, 2RecruitingTreatmentNeoplasms, Breast2
1, 2TerminatedTreatmentCancer, Breast1
2Active Not RecruitingNot AvailableNeoplasms, Breast1
2Active Not RecruitingTreatmentAdvanced Breast Cancer / Metastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentBreast Cancer Invasive Nos1
2Active Not RecruitingTreatmentCancer, Breast9
2Active Not RecruitingTreatmentEndometrial Cancers1
2Active Not RecruitingTreatmentEstrogen Receptor Positive / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMcCune-Albright Syndrome / Puberty, Precocious1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)3
2Active Not RecruitingTreatmentNeoplasms, Breast1
2CompletedTreatmentAdvanced Breast Cancer2
2CompletedTreatmentAdvanced Breast Cancer / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast11
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentEndometrial Carcinoma1
2CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / Recurrent Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMetastatic Breast Cancer (MBC)4
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentProstate Cancer / Prostatic Neoplasms1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
2Not Yet RecruitingTreatmentBreast Cancer Metastatic1
2Not Yet RecruitingTreatmentNeoplasms, Breast2
2RecruitingBasic ScienceCancer, Breast1
2RecruitingOtherAdvanced Breast Cancer1
2RecruitingTreatmentBreast Cancer Metastatic1
2RecruitingTreatmentCancer of Breast / Cancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2RecruitingTreatmentCancer of Breast / Cancer, Breast / Carcinoma, Breast / Malignant Tumor of Breast1
2RecruitingTreatmentCancer, Breast7
2RecruitingTreatmentCancer, Breast / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCarcinoma, Breast / Metastatic Breast Cancer (MBC)1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / Estrogen Receptor Status / HER2/Neu Negative / Invasive Breast Carcinoma / One to five years postmenopausal / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2RecruitingTreatmentEstrogen Receptor Positive Breast Cancer1
2RecruitingTreatmentEstrogen Receptor and/or Progesterone Receptor Positive / HER2/Neu Negative / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2RecruitingTreatmentFemale Breast Carcinoma / Female Ductal Carcinoma In Situ1
2RecruitingTreatmentHER-2 Positive Breast Cancer / Hormone Receptor Positive Tumor1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)6
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentNeoplasms, Breast3
2RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2RecruitingTreatmentStage IV Lung Cancer1
2RecruitingTreatmentTumors, Solid1
2TerminatedTreatmentCancer, Breast4
2TerminatedTreatmentCarcinoma, Breast1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Postmenopausal Women1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)3
2TerminatedTreatmentNeoplasms, Breast3
2TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentProstate Cancer1
2Unknown StatusTreatmentCancer, Breast3
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
2WithdrawnTreatmentBreast Cancer Metastatic1
2WithdrawnTreatmentCancer, Breast1
2, 3CompletedTreatmentTumors, Solid1
3Active Not RecruitingTreatmentAntineoplastic Agents / Antineoplastic Agents, Hormonal / Breast Diseases / Estrogen Receptor Antagonists / Fulvestrant / Hormone Antagonists / Hormones, Hormone Substitutes, and Hormone Antagonists / Molecular Mechanisms of Pharmacological Action / Neoplasms / Neoplasms by Site / Neoplasms, Breast / Pharmacologic Actions / Therapeutic Uses1
3Active Not RecruitingTreatmentCancer, Breast3
3Active Not RecruitingTreatmentEstrogen Receptor Positive / HER2 Positive Breast Carcinoma / HER2/Neu Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
3Active Not RecruitingTreatmentHormone Receptor Positive Breast Cancer1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC) / Metastatic Breast Cancer HR+, HER2-1
3Active Not RecruitingTreatmentNeoplasms, Breast1
3CompletedTreatmentAdvanced Breast Cancer2
3CompletedTreatmentCancer, Breast2
3CompletedTreatmentCancer, Breast / Metastasis1
3CompletedTreatmentLocally Advanced Breast Cancer (LABC) / Metastatic Breast Cancer (MBC)1
3CompletedTreatmentProgression-free Survival1
3RecruitingDiagnosticMetastatic Breast Cancer (MBC)1
3RecruitingTreatmentCancer, Breast3
3RecruitingTreatmentCancer, Breast / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Locally Advanced Malignant Neoplasm / Metastatic Breast Cancer (MBC)1
3RecruitingTreatmentEstrogen Receptor Positive Breast Cancer / HER-2 Positive Breast Cancer1
3RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Invasive Ductal Breast Carcinoma / Invasive Lobular Breast Carcinoma / Recurrent Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)3
3TerminatedTreatmentCancer, Breast2
3Unknown StatusTreatmentCancer, Breast3
4Active Not RecruitingNot AvailableLocally Advanced or / Metastatic Breast Cancer (MBC)1
Not AvailableCompletedNot AvailableCancer, Breast2
Not AvailableCompletedNot AvailableMalignant Neoplasm of Breast Stage IV1
Not AvailableRecruitingNot AvailableMetastatic Breast Cancer (MBC)1
Not AvailableRecruitingTreatmentCancer, Breast1
Not AvailableTerminatedTreatmentER-positive Breast Cancer / Her2-Positive Breast Cancer1
Not AvailableUnknown StatusTreatmentCancer, Breast1

Pharmacoeconomics

Manufacturers
  • Astrazeneca pharmaceuticals lp
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular50 mg/mL
Injection, solutionIntramuscular250 mg/5ml
SolutionIntramuscular50 mg
Prices
Unit descriptionCostUnit
Faslodex 125 mg/2.5 ml syringe240.83USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2351004No2003-02-182021-01-08Canada
US6774122Yes2001-07-092021-07-09Us
US7456160Yes2001-07-092021-07-09Us
US8329680Yes2001-07-092021-07-09Us
US8466139Yes2001-07-092021-07-09Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP8.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00672 mg/mLALOGPS
logP6.54ALOGPS
logP7.57ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)10.32ChemAxon
pKa (Strongest Basic)-0.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity155.34 m3·mol-1ChemAxon
Polarizability65.64 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9217
Caco-2 permeable-0.5095
P-glycoprotein substrateSubstrate0.722
P-glycoprotein inhibitor INon-inhibitor0.6251
P-glycoprotein inhibitor IINon-inhibitor0.967
Renal organic cation transporterNon-inhibitor0.7568
CYP450 2C9 substrateNon-substrate0.7667
CYP450 2D6 substrateNon-substrate0.7737
CYP450 3A4 substrateSubstrate0.6945
CYP450 1A2 substrateNon-inhibitor0.6842
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.658
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6701
Ames testNon AMES toxic0.6318
CarcinogenicityNon-carcinogens0.75
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6310 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6158
hERG inhibition (predictor II)Inhibitor0.7955
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-hydroxysteroids / 17-hydroxysteroids / Phenanthrenes and derivatives / Tetralins / 1-hydroxy-2-unsubstituted benzenoids / Sulfoxides / Secondary alcohols / Cyclic alcohols and derivatives / Sulfinyl compounds / Organofluorides
show 3 more
Substituents
Estrogen-skeleton / 3-hydroxysteroid / 17-hydroxysteroid / Hydroxysteroid / Phenanthrene / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Benzenoid / Cyclic alcohol / Sulfoxide
show 13 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organofluorine compound, sulfoxide, 17beta-hydroxy steroid, 3-hydroxy steroid (CHEBI:31638)

Targets

Details
1. Estrogen receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Curran M, Wiseman L: Fulvestrant. Drugs. 2001;61(6):807-13; discussion 814. [PubMed:11398912]
  2. Elkak AE, Mokbel K: Pure antiestrogens and breast cancer. Curr Med Res Opin. 2001;17(4):282-9. [PubMed:11922402]
  3. Dow KH: Existing and emerging endocrine therapies for breast cancer. Cancer Nurs. 2002 Apr;25 Suppl 2:6S-11S. [PubMed:12080538]
  4. Bundred N, Howell A: Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther. 2002 Apr;2(2):151-60. [PubMed:12113237]
  5. Morris C, Wakeling A: Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer. 2002 Dec;9(4):267-76. [PubMed:12542403]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Kabos P, Borges VF: Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother. 2010 Apr;11(5):807-16. doi: 10.1517/14656561003641982. [PubMed:20151846]
  8. McKeage K, Curran MP, Plosker GL: Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs. 2004;64(6):633-48. [PubMed:15018596]
  9. Jones SE, Pippen J: Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2005 Apr;6 Suppl 1:S9-14. [PubMed:15865850]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33